Positive Responses With Belumosudil in GVHD Spark Pending FDA Submission

May 21, 2020

"These results demonstrate the potential of belumosudil to become a cornerstone of the cGVHD treatment paradigm if approved, as it delivers meaningful and sustained benefits to patients with this serious condition."

Evaluating Ways of Measuring MRD in Hematologic Malignancies

May 21, 2020

Jerald P. Radich, MD, discusses how minimal residual disease is measured in hematologic malignancies.

Omidubicel Improves Neutrophil Engraftment Time in Blood Cancers Undergoing Transplant

May 12, 2020

"These results have the potential to substantially move the field forward and represent an important step toward making stem cell transplantation more accessible and more successful for patients with lethal blood cancers. Shortening the time to engraftment is clinically meaningful, as it can reduce a patient’s time in the hospital and decrease likelihood of infection."

FDA Grants Orphan Drug Designation to HQP1351 in Chronic Myeloid Leukemia

May 04, 2020

There is a significant unmet clinical need [for] treatment of CML globally. This Orphan Drug Designation from FDA marks a major milestone for HQP1351..."

TP53-Mutant AML Subgroup May Benefit from Novel Immunotherapy Agent

May 04, 2020

“Immune transcriptomic analyses of in silico and wet-lab cohorts of TP53-mutated AML suggest the presence of high T-cell infiltration and high expression of immune checkpoints and interferon-gamma signaling molecules compared with AML subgroups with other risk-defining molecular lesions."

FDA Approves Subcutaneous Daratumumab With Hyaluronidase in Multiple Myeloma Indications

May 01, 2020

The FDA has approved the use of daratumumab in combination with hyaluronidase-fihj (Darzalex Faspro) for the treatment of adult patients with newly diagnosed or relapsed/refractory multiple myeloma. The newly approved product allowed for subcutaneous dosing of daratumumab.

Evaluating Safety Concerns in Patients With Hairy Cell Leukemia

April 29, 2020

Kerry Rogers, MD, discusses an important unmet need in patients with hairy cell leukemia.

Ruxolitinib Significantly Improves Outcomes in Acute Graft-Versus-Host-Disease

April 23, 2020

“These new data from REACH2 showing superiority of Jakavi over current standard-of-care therapies add to a growing body of evidence on how targeting the JAK pathway can be an effective strategy in this difficult-to-treat condition."

Longest Follow-Up Maintains Ibrutinib Benefit in CLL/SLL Across Treatment Settings

April 13, 2020

The longest follow-up for ibrutinib monotherapy to date maintained the benefit of the Bruton’s tyrosine kinase inhibitor for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma across settings.